# Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

> **NCT07232030** · NA · ENROLLING_BY_INVITATION · sponsor: **CVRx, Inc.** · enrollment: 2500 (estimated)

## Conditions studied

- Heart Failure
- Heart Failure NYHA Class II
- Heart Failure NYHA Class III

## Interventions

- **DEVICE:** Barostim System
- **OTHER:** Usual care medical management

## Key facts

- **NCT ID:** NCT07232030
- **Lead sponsor:** CVRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-04
- **Primary completion:** 2033-01
- **Final completion:** 2033-01
- **Target enrollment:** 2500 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232030, "Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07232030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*